Cetuximab therapy and symptomatic hypomagnesemia

Journal of the National Cancer Institute

Volumn 97, Issue 16, 2005, Pages 1221-1224

  Schrag, Deborah ^a   Chung, Ki Young ^a   Flombaum, Carlos ^a   Saltz, Leonard ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE; AMPHOTERICIN; BEVACIZUMAB; CALCIUM; CETUXIMAB; CISPLATIN; DIURETIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; MAGNESIUM; MAGNESIUM SULFATE; MONOCLONAL ANTIBODY; OXALIPLATIN; TACROLIMUS; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DRUG DERIVATIVE;

ACNE; ADULT; ARTICLE; BLOOD CHEMISTRY; CASE STUDY; COLORECTAL CANCER; DIARRHEA; DRUG ERUPTION; DRUG WITHDRAWAL; ELECTROLYTE DISTURBANCE; FASCICULATION; FATIGUE; HAND DISEASE; HUMAN; HYPOCALCEMIA; HYPOMAGNESEMIA; LIVER DISEASE; MAGNESIUM BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; METASTASIS; PARESTHESIA; PRIORITY JOURNAL; RECEPTOR BLOCKING; SUPPLEMENTATION; SYMPTOMATOLOGY; URINARY EXCRETION; WASTING SYNDROME; BLOOD; CASE REPORT; CHEMICALLY INDUCED DISORDER; COLORECTAL TUMOR; DRUG ANTAGONISM; HOSPITALIZATION; INCIDENCE; MAGNESIUM DEFICIENCY; METABOLISM; REVIEW;

ADULT; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; FATIGUE; HUMANS; HYPOCALCEMIA; INCIDENCE; MAGNESIUM; MAGNESIUM DEFICIENCY; MALE; RECEPTOR, EPIDERMAL GROWTH FACTOR; SEVERITY OF ILLNESS INDEX;

EID: 23844555670     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/dji242     Document Type: Article

References (13)

1. Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 2003;21:2787-99.
2. Mendelsohn J. Targeting the epidermal growth factor receptor for cancer therapy. J Clin Oncol 2002;20(18 Suppl):1S-13S.
3. Prewett MC, Hooper AT, Bassi R, Ellis LM, Waksal HW, Hicklin DJ. Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts. Clin Cancer Res 2002;8:994-1003.
4. Saltz LB, Meropol NJ, Loehrer PJ Sr, Needle MN, Kopit J, Mayer RJ. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004;22:1201-8.
5. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337-45.
6. Lajer H, Daugaard G. Cisplatin and hypomagnesemia. Cancer Treat Rev 1999;25: 47-58.
7. Whang R, Hampton EM, Whang DD. Magnesium homeostasis and clinical disorders of magnesium deficiency. Ann Pharmacother 1994;28:220-6.
8. Kelepouris E, Agus ZS. Hypomagnesemia: Renal magnesium handling. Semin Nephrol 1998;18:58-73.
9. Schlingmann KP, Weber S, Peters M, Niemann Nejsum L, Vitzthum H, Klingel K, et al. Hypomagnesemia with secondary hypocalcemia is caused by mutations in TRPM6, a new member of the TRPM gene family. Nat Genet 2002;31:166-70.
10. Chubanov V, Waldegger S, Mederos y Schnitzler M, Vitzthum H, Sassen MC, Seyberth HW, et al. Disruption of TRPM6/TRPM7 complex formation by a mutation in the TRPM6 gene causes hypomagnesemia with secondary hypocalcemia. Proc Natl Acad Sci USA 2004;101:2894-9.
11. Vanhoefer U, Tewes M, Rojo F, Dirsch O, Schleucher N, Rosen O, et al. Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor. J Clin Oncol 2004;22:175-84.
12. National Cancer Institute Common Toxicity and Adverse Event Criteria for Serum Calcium and Magnesium. Available at: http://ctep.cancer.gov/forms/CTCAEV3.pdf (last accessed: May 5, 2005).
13. Tournigand C, Andre T, Achille E, Lledo G, Flesh M, Mery-Mignard D, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study. J Clin Oncol 2004;22:229-37.